Welcome to Conversations in Drug Development, brought to you by the team at Boyds. This podcast is for our fellow community of scientists and clinicians working in the wonderful world of cell and gene therapy and drug development.
All content for Conversations in Drug Development is the property of Boyds and is served directly from their servers
with no modification, redirects, or rehosting. The podcast is not affiliated with or endorsed by Podjoint in any way.
Welcome to Conversations in Drug Development, brought to you by the team at Boyds. This podcast is for our fellow community of scientists and clinicians working in the wonderful world of cell and gene therapy and drug development.
Crystal Ball Gazing: What Does the Future Hold for Regulatory Affairs in Drug Development for 2025
Conversations in Drug Development
32 minutes 57 seconds
7 months ago
Crystal Ball Gazing: What Does the Future Hold for Regulatory Affairs in Drug Development for 2025
In this episode, Harriet Edwards from Boyds hosts a discussion on 2025 predictions in drug development and regulatory affairs. Joined by regulatory experts Dr. Katherine Bowen and Dr. Eric Harder, the conversation covers the anticipated trends in the realm of cell and gene therapy, rare diseases, and the increasing role of artificial intelligence (AI).
As we look ahead to 2025, Boyds' regulatory experts discuss the evolving regulatory landscape, legislative changes in the US and EU, and the importance of patient-centric approaches.
Join us for this insightful journey as we uncover what 2025 has in store for drug development and regulatory strategies.
Conversations in Drug Development
Welcome to Conversations in Drug Development, brought to you by the team at Boyds. This podcast is for our fellow community of scientists and clinicians working in the wonderful world of cell and gene therapy and drug development.
